Invention Grant
- Patent Title: Antibody drug conjugates for ablating hematopoietic stem cells
-
Application No.: US16470897Application Date: 2017-12-19
-
Publication No.: US11357864B2Publication Date: 2022-06-14
- Inventor: Ben Wen , Anthony E. Boitano , Matthew Burger , Susan E. Cellitti , Michael P. Cooke , Catrin Finner , Bernhard Hubert Geierstanger , Yunho Jin , Si Tuen Lee-Hoeflich , HongNgoc Thi Pham , Siew Ho Schleyer , Kathrin Tissot , Tetsuo Uno
- Applicant: NOVARTIS AG
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agent Jana E. Harris
- International Application: PCT/IB2017/058159 WO 20171219
- International Announcement: WO2018/116178 WO 20180628
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C07K16/00 ; C07K16/46 ; A61K47/68 ; A61K38/07 ; A61K38/12 ; C07K16/28
Abstract:
The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
Public/Granted literature
- US20190321483A1 ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS Public/Granted day:2019-10-24
Information query
